Outset Medical Inks $40M HCA Deal, Paving Path to Profitability

SAN JOSE, CA – August 06, 2026

Outset Medical, the company aiming to simplify dialysis, reported second-quarter earnings today that revealed a business in a crucial phase of transition. While top-line revenue growth appeared modest at just 1% year-over-year, a deeper look at the results and a landmark new contract tell a story of strategic fortification and a clear path toward sustainable growth and profitability.

The headline announcement was a three-year, $40 million agreement with HCA Healthcare, the nation’s largest health system, to refresh its existing fleet of Tablo Hemodialysis Systems. This deal, coupled with expanding gross margins and the highest number of new site installations in several years, suggests Outset is successfully building a more resilient and predictable business model.

“Second quarter results reflect continued progress in strengthening the foundation of our business while positioning Outset for the next phase of growth,” said Leslie Trigg, Chair and Chief Executive Officer. “By reshaping how dialysis care is delivered across a large market that needs better solutions, Outset is well positioned to accelerate adoption, drive long-term growth and advance toward profitability.”

The Strategic Power of a Refresh

The agreement with HCA Healthcare is more than just a large order; it represents a pivotal strategic milestone for Outset Medical. This is the company’s first major “refresh” agreement, where a foundational customer commits to upgrading its existing technology fleet. This move validates the long-term value and reliability of the Tablo system and establishes a new, predictable revenue stream built on the company’s installed base.

Scheduled to run through the end of 2028, the $40 million commitment provides significant backlog visibility, a key metric for investors and analysts tracking the company’s health. It signals a shift from a primary focus on new customer acquisition to a dual strategy that also includes securing long-term value from its existing partners. For a company in the capital equipment space, demonstrating a successful upgrade cycle is critical proof of a technology's staying power and its indispensability to a customer's operations.

Furthermore, the deal with an industry titan like HCA Healthcare sends a powerful signal to the broader market. It underscores the Tablo system’s ability to perform at scale within a demanding, high-volume healthcare environment. Beyond the initial $40 million, Outset executives have noted that this agreement sets the stage for a much larger opportunity. The total refresh cycle for their installed base could encompass approximately 3,000 consoles, potentially representing up to $150 million in hardware revenue over the next several years. This single deal, therefore, acts as a blueprint for future growth and a powerful case study for other large health systems considering the Tablo platform.

Beyond the Headline: A Look at Financial Health

While the HCA deal captured the spotlight, Outset Medical’s Q2 financial metrics paint a picture of a company diligently improving its operational engine. The reported net revenue of $31.6 million, though only a 1% increase over the prior year, showed a more robust 14% sequential increase from the first quarter of 2026, indicating building momentum.

The most compelling financial story lies in the company's profitability metrics. Gross margin expanded to 42%, an impressive jump of more than 400 basis points from 37.8% in the same period last year. This was driven by a remarkable improvement in the service and other revenue segment, where gross margin soared to 32.6% from a mere 6.9% a year ago. This dramatic gain points to significant efficiencies in how the company services its growing fleet of Tablo systems, a crucial element for long-term profitability. While product gross margin dipped slightly due to a higher mix of console sales, the overall trend is one of increasing operational leverage.

The company is also demonstrating fiscal discipline. Operating expenses remained roughly flat year-over-year at $29.0 million, even as the company supported a higher number of new site installations. This controlled spending, combined with improving margins, led to a reduced net loss of $18.0 million for the quarter. Cash burn is also being managed effectively, with net cash used during the quarter at a moderate $9.5 million, leaving the company with a solid $151 million in cash and investments. By reiterating its full-year revenue guidance of $125 million to $130 million, the San Jose-based firm is signaling confidence that growth will accelerate in the second half of the year, a common pattern in the medical capital equipment market.

Reshaping Dialysis One System at a Time

The financial numbers and strategic contracts are ultimately underwritten by the value of the technology itself. Outset Medical’s Tablo system was designed from the ground up to address the core challenges of dialysis: cost and complexity. By integrating water purification and on-demand dialysate production into a single, mobile unit, Tablo eliminates the need for the complex infrastructure and centralized water treatment rooms that traditional dialysis requires.

This all-in-one design is what enables its unique versatility. The system is FDA-cleared for use across the entire care continuum, from the intensive care unit to a patient’s living room. For hospitals, this means they can stand up an in-house dialysis program with greater ease and flexibility, reducing reliance on costly third-party services. For nurses, the simplified interface and automated processes can reduce training time and cognitive load. For patients, the potential to perform dialysis at home offers a life-changing improvement in autonomy and quality of life.

The market is responding to this value proposition. The second quarter saw the highest number of new site installations in several years, including adoption by a new top 10 health system. With over 1,000 healthcare facilities in the U.S. now using Tablo, the technology is moving from a novel innovation to a trusted standard of care. This growing footprint is the foundation upon which the company is building its future, creating the installed base for the consumables and refresh cycles that will drive predictable, recurring revenue for years to come. The company's focus on a clinical excellence team to help customers optimize the system's use further embeds its value, transforming a product sale into a long-term partnership.

Navigating the Path to Lasting Value

Outset Medical is carving out its niche in a market long dominated by established giants like Fresenius and DaVita. Its strategy is not to compete head-on with their vast network of dialysis centers, but to empower healthcare providers to take control of dialysis themselves with a more efficient and flexible technology. The Q2 2026 results show this strategy is gaining traction.

The modest top-line growth is secondary to the more important narrative of foundational strengthening. The company is proving it can manage costs, dramatically improve service margins, and, most critically, convert initial customers into long-term partners through system refreshes. This transition from a growth-at-all-costs mindset to one focused on building a durable, profitable enterprise is a sign of maturity.

With a pilot program for a new version of the Tablo system underway to gather user feedback, the company is also looking toward the next wave of innovation. The road ahead involves deepening its penetration within large health systems, systematically capitalizing on the multi-million dollar refresh opportunity, and continuing to demonstrate how simplifying a complex medical procedure can lead to better outcomes for providers and the patients they serve. The quarter's results suggest that Outset Medical is not just selling a machine, but building a sustainable ecosystem around a new standard of care.